Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients

Fukuda, Hiroshi; Honda, C.; Wadabayashi, N.; Kobayashi, Tooru; Yoshino, Kazuo; Hoshino, Junichi; Takahashi, Jutaro; Akaizawa, Takashi; Abe, Yoshinao; Ichihashi, Masamitsu; Mishima, Yutaka

doi:10.1097/00008390-199902000-00010

Cited by 56 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, it has been observed that even tumors located in the same leg of one patient showed a different grade of response to the same treatment (6). ranging between less than 12 ppm and no more than 52 ppm.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

Carpano

Perona

Rodríguez

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…The first melanoma patients were treated in the USA in 1985 (5). Several other patients with either cutaneous or metastatic melanoma to the brain have been treated in other countries including Argentina (6,7). All the results showed that BNCT seemed to be suitable to treat metastases of superficial cutaneous melanoma.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

Carpano

Perona

Rodríguez

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…In this paper, we described the procedures for our BNCT of the malignant melanoma based on the pharmacokinetics of BPA and radiobiological considerations [9][10][11] . Although the same logical procedures for dose optimization were performed, the radiation doses to the normal skin varied considerably and exceeded the maximum tolerance limits in some cases.…”

Section: Discussionmentioning

confidence: 99%

Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

Fukuda

Hoshino

Kobayashi

et al. 2003

Australas. Phys. Eng. Sci. Med.

Self Cite

View full text Add to dashboard Cite

Twenty-two patients with malignant melanoma were treated with boron neutron capture therapy (BNCT) using 10B-p-boronophenylalanine (BPA). The estimation of absorbed dose and optimization of treatment dose based on the pharmacokinetics of BPA in melanoma patients is described. The doses of gamma-rays were measured using small TLDs of Mg2SiO4 (Tb) and thermal neutron fluence was measured using gold foil and wire. The total absorbed dose to the tissue from BNCT was obtained by summing the primary and capture gamma-ray doses and the high LET radiation doses from 10B(n, alpha)7Li and 14N(n,p)14C reactions. The key point of the dose optimization is that the skin surrounding the tumour is always irradiated to 18 Gy-Eq, which is the maximum tolerable dose to the skin, regardless of the 10B-concentration in the tumor. The neutron fluence was optimized as follows. (1) The 10B concentration in the blood was measured 15-40 min after the start of neutron irradiation. (2) The 10B-concentration in the skin was estimated by multiplying the blood 10B value by a factor of 1.3. (3) The neutron fluence was calculated. Absorbed doses to the skin ranged from 15.7 to 37.1 Gy-Eq. Among the patients, 16 out of 22 patients exhibited tolerable skin damage. Although six patients showed skin damage that exceeded the tolerance level, three of them could be cured within a few months after BNCT and the remaining three developed severe skin damage requiring skin grafts. The absorbed doses to the tumor ranged from 15.7 to 68.5 Gy-Eq and the percentage of complete response was 73% (16/22). When BNCT is used in the treatment of malignant melanoma, based on the pharmacokinetics of BPA and radiobiological considerations, promising clinical results have been obtained, although many problems and issues remain to be solved.

show abstract

“…Table 1 lists the obtained boron dose ratios (R B ) considering boron concentration ratios, B 10 tumor : B 10 normal , of 3:1 for heart and lung and 3:1.8 for skin (Fukuda et al, 1999). Fig.…”

Section: Neutron Flux Study and Dosimetry Considerationsmentioning

confidence: 99%

Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

Gadan

González

Batalla

et al. 2015

Applied Radiation and Isotopes

View full text Add to dashboard Cite

In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research.

show abstract

Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients

Cited by 56 publications

References 0 publications

Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

Contact Info

Product

Resources

About